Diabetology International

, Volume 1, Issue 2, pp 83–89 | Cite as

Multifaceted intervention to promote the regular visiting of patients with diabetes to primary care physicians: rationale, design and conduct of a cluster-randomized controlled trial. The Japan Diabetes Outcome Intervention Trial-2 study protocol

  • Kazuo Izumi
  • Yasuaki Hayashino
  • Katsuya Yamazaki
  • Hikari Suzuki
  • Naoki Ishizuka
  • Masashi Kobayashi
  • Mitsuhiko Noda
  • The J-DOIT2 Study Group
Original article



Regular clinic visits are essential for keeping diabetes well controlled. Nevertheless, about half of the known diabetic patients do not receive regular medical care, as estimated by the National Survey in Japan. From the viewpoint of medical resources, primary care physicians (PCPs) should provide regular medical care to the many diabetic patients in Japan. Therefore, maintaining regular care and improving care quality are expected for diabetes treatment at the PCP level.


The Japan Diabetes Outcome Intervention Trial-2 (J-DOIT2) is a cluster-randomized two-armed intervention study. Fifteen district medical associations (DMAs) and 300 PCPs will participate. The PCPs in each DMA will be divided into two groups and randomized, with each group acting as a cluster within the DMA. Then, 3,750 type 2 diabetes patients (aged 40–64 years) will be recruited. In the intervention group, patients will receive reminders for medical visits to their PCP and lifestyle advice over the telephone or face to face. The PCPs will be provided with benchmark indicators of his/her own diabetes treatment activities. In the control group, the PCPs will provide ordinary medical treatment to his/her patients. With a 1-year intervention and follow-up period, the primary outcome will be the rate of patient dropout from regular medical care of both groups. The quality of diabetes treatment provided by the PCPs will also be evaluated.


The J-DOIT2 is a large-scale trial for improvement of diabetes care in an ordinary primary care setting and is expected to contribute to establishing widely adoptable countermeasures for diabetes.


Diabetes Dropout Regular medical care Primary care physician Quality of diabetes care 



Control group


Clinical research coordinator


District medical association


Intervention group


Japan Diabetes Outcome Intervention Trial


J-DOIT2 large-scale trial


J-DOIT2 pilot study


Lifestyle adviser


Next visit day


Primary care physician


Treatment support center



This study is funded by a Health and Labour Sciences Research Grant (Strategic Outcomes Research Program for Research on Diabetes and Comprehensive Research on Diabetes/Cardiovascular and Life-Style Related Diseases) from the Ministry of Health, Labour and Welfare of Japan. The funding body has determined the goal of this study, that is, verification of the intervention for reducing patient dropout from regular diabetes treatment.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Yazaki Y, Kadowaki T. Combating diabetes and obesity in Japan. Nat Med. 2006;12(1):73–4.PubMedCrossRefGoogle Scholar
  3. 3.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  4. 4.
    Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Outline for the Results of the National Health and Nutrition Survey Japan, 2007. Accessed 1 Sept 2010.
  6. 6.
    Smith DM, Weinberger M, Katz BP. A controlled trial to increase office visits and reduce hospitalizations of diabetic patients. J Gen Intern Med. 1987;2(4):232–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). J Health Serv Res Policy. 2000;5(1):12–6.PubMedGoogle Scholar
  8. 8.
    Campbell MK, Mollison J, Grimshaw JM. Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Stat Med. 2001;20(3):391–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol. 1999;28(2):319–26.PubMedCrossRefGoogle Scholar
  10. 10.
    White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48(4):817–38.CrossRefGoogle Scholar

Copyright information

© The Japan Diabetes Society 2011

Authors and Affiliations

  • Kazuo Izumi
    • 1
  • Yasuaki Hayashino
    • 2
  • Katsuya Yamazaki
    • 3
  • Hikari Suzuki
    • 3
  • Naoki Ishizuka
    • 4
  • Masashi Kobayashi
    • 5
  • Mitsuhiko Noda
    • 1
    • 6
  • The J-DOIT2 Study Group
  1. 1.Office of Strategic Outcomes Research ProgramJapan Foundation for the Promotion of International Medical Research CooperationTokyoJapan
  2. 2.Department of Epidemiology and Healthcare ResearchKyoto University Graduate School of MedicineKyotoJapan
  3. 3.First Department of Internal Medicine, Faculty of MedicineToyama UniversityToyamaJapan
  4. 4.Division of Medical Informatics, Department of Clinical Research and Informatics, Research InstituteNational Center for Global Health and MedicineTokyoJapan
  5. 5.Section of Medicine, Graduate School of Medicine and Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
  6. 6.Department of Diabetes and Metabolic MedicineNational Center for Global Health and MedicineTokyoJapan

Personalised recommendations